462,400 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by LSV Asset Management

LSV Asset Management bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 462,400 shares of the biopharmaceutical company's stock, valued at approximately $17,090,000. LSV Asset Management owned 0.35% of Halozyme Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HALO. Artisan Partners Limited Partnership grew its holdings in shares of Halozyme Therapeutics by 3.4% during the 3rd quarter. Artisan Partners Limited Partnership now owns 7,712,874 shares of the biopharmaceutical company's stock worth $294,632,000 after purchasing an additional 253,363 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Halozyme Therapeutics by 0.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,698,359 shares of the biopharmaceutical company's stock worth $64,877,000 after acquiring an additional 15,902 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Halozyme Therapeutics by 174.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company's stock valued at $33,894,000 after acquiring an additional 563,989 shares in the last quarter. Kennedy Capital Management LLC increased its stake in Halozyme Therapeutics by 4.7% in the third quarter. Kennedy Capital Management LLC now owns 646,475 shares of the biopharmaceutical company's stock valued at $24,695,000 after acquiring an additional 28,880 shares during the period. Finally, Principal Financial Group Inc. raised its position in Halozyme Therapeutics by 10.9% in the third quarter. Principal Financial Group Inc. now owns 590,651 shares of the biopharmaceutical company's stock worth $22,563,000 after purchasing an additional 58,123 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HALO. StockNews.com upgraded Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research note on Friday, February 23rd. HC Wainwright restated a "buy" rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday. The Goldman Sachs Group dropped their target price on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a "neutral" rating for the company in a research report on Thursday, January 18th. TheStreet lowered shares of Halozyme Therapeutics from a "b-" rating to a "c+" rating in a research report on Monday, January 22nd. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $53.29.

Halozyme Therapeutics Price Performance

Shares of HALO stock traded up $0.35 during trading hours on Tuesday, reaching $41.21. 1,281,201 shares of the company were exchanged, compared to its average volume of 1,207,506. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50. The company has a market cap of $5.24 billion, a price-to-earnings ratio of 19.53, a P/E/G ratio of 0.47 and a beta of 1.26. The stock's fifty day moving average is $40.04 and its two-hundred day moving average is $37.99. Halozyme Therapeutics, Inc. has a fifty-two week low of $29.85 and a fifty-two week high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the sale, the senior vice president now directly owns 156,558 shares of the company's stock, valued at $6,519,075.12. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have sold 30,000 shares of company stock worth $1,196,800. Company insiders own 2.70% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.